IPOs and Catalysts/Events, Global Equity Research Ltd

Arun George

IPOs and Catalysts/Events

Uncompromised, Independent, Conflict-Free Research

Global Equity Research Ltd

Global Equity Research was started in 2017 by a group of experienced research professionals. It was founded on a passionate belief in the importance and the need for uncompromised, independent, conflict-free research. We aim to provide differentiated and actionable primary and bottom up fundamental research.

Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/27092" target="_blank" data-smartkarma-citation="entities:27092:1">WuXi AppTec Co Ltd (603259 CH)</a> is a leading global pharmaceutical R&amp;D outsourcing service provider and the largest in Asia by revenue in 2017. WuXi AppTec, which recently completed an A Share listing, will start pre-marketing on Monday for a Hong Kong IPO to raise $1 billion, according to press reports. It is backed by Temasek (7.8% shareholder) and Hillhouse Capital (6.0% shareholder).</p><div class="content-highlight"><p>In a tougher drug development backdrop, companies such as WuXi AppTec have emerged as efficient providers of value-added outsourcing services for pharmaceutical companies. As pharmaceutical companies focus on optimising costs, WuXi AppTec should benefit from increased outsourcing of R&amp;D. This favourable market backdrop, when combined with WuXi AppTec’s solid fundamentals, makes it an enticing IPO (subject to valuation).</p></div>

WuXi AppTec Co Ltd (603259 CH) is a leading global pharmaceutical R&amp;D outsourcing service provider and the largest in Asia by revenue in 2017. WuXi AppTec, which recently completed an A Share listing, will start pre-marketing on Monday for a Hong Kong IPO to raise $1 billion, according to press reports. It is backed by Temasek (7.8% shareholder) and Hillhouse Capital (6.0% shareholder).In a tougher drug development backdrop, companies such as WuXi AppTec have emerged as efficient providers of value-added outsourcing services for pharmaceutical companies. As pharmaceutical companies focus on optimising costs, WuXi AppTec should benefit from increased outsourcing of R&amp;D. This favourable market backdrop, when combined with WuXi AppTec’s solid fundamentals, makes it an enticing IPO (subject to valuation).

Technical Analyst, Vermilion Research

Joe Jasper

Technical Analyst

Technical and Quantitative Research

Vermilion Research

Vermilion’s objective is to deliver timely, actionable, and unique technical research to professional investors through the application of our various technical indicators.

Our research strategists seek to highlight securities which we believe are at major inflection points, based on our various technical and quantitative indicators, and offer asymmetric risk/return profiles. Our unique research methodology, centered on relative strength, enables our strategists to deliver superior investment recommendations.

Our process begins by organizing the universe of actively traded stocks into discrete sectors, then into industry groups. We then apply our technical and quantitative tools to identify developing price trends. Once attractive trends are identified within a selected sector or group, we screen for individual stocks which we believe offer the best risk/reward profile. We provide a historical perspective that often reveals, through our long-term charts, how price patterns often repeat themselves over time.

Technical Analysis

<p>As the S&amp;P 500 nears the 2,873 January high - a critical hurdle - short-term Sector leadership changes give us reason for pause. While we remain constructive overall, our expectations are tempered as the market finds itself a crossroad.  In today’s report we provide our U.S. equity strategy synopsis, and also highlight attractive stocks within the Health Care Sector.</p>

As the S&amp;P 500 nears the 2,873 January high - a critical hurdle - short-term Sector leadership changes give us reason for pause. While we remain constructive overall, our expectations are tempered as the market finds itself a crossroad.  In today’s report we provide our U.S. equity strategy synopsis, and also highlight attractive stocks within the Health Care Sector.

S&P 500: Outlook Constructive but Concerns Remain

United States

Charles River Laboratories International, Inc. provides research tools and support services that enable drug discovery and development.  The Company provides the animal research models required in research and development for new drugs, devices, and therapies.  Charles River's customers include pharmaceutical and biotechnology companies, hospitals, and academic institutions.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Charles River Laboratories (CRL US)

WuXi AppTech IPO Preview: Pharmed Out

WuXi AppTec Co Ltd (603259 CH) is a leading global pharmaceutical R&D outsourcing service provider and the largest in Asia by revenue in 2017....

Arun George

S&P 500: Outlook Constructive but Concerns Remain

As the S&P 500 nears the 2,873 January high - a critical hurdle - short-term Sector leadership changes give us reason for pause. While we...

Vermilion Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)